Suzhou Erye is a vertically-integrated pharmaceutical company in the People's Republic of China focused primarily on the manufacturing and sale of antibiotics in both finished dosage and active pharmaceutical intermediate (API) forms. The company currently sells a broad portfolio of anti-infective drugs with no single produce accounting for more than 10% of total revenues and has seven products in its pipeline, including two SFDA approved drugs. Erye’s new product facility will significantly increase its capacitywith the goal of becoming  one of the largest antibiotic producers in Eastern China. Erye generated 2009 revenues of approximately $61 million, nearly doubling that of its 2007 sales level.